Wall Street Zen upgraded shares of Humacyte (NASDAQ:HUMA – Free Report) to a sell rating in a report released on Saturday,Wall Street Zen reports.
HUMA has been the topic of several other research reports. BTIG Research reiterated a “buy” rating and set a $2.00 price target on shares of Humacyte in a report on Tuesday, November 10th. Barclays boosted their price objective on shares of Humacyte from $0.50 to $0.60 and gave the company an “equal weight” rating in a report on Wednesday, November 11th. HC Wainwright reaffirmed a “buy” rating on shares of Humacyte in a research report on Friday, October 16th. Cantor Fitzgerald set a $1.00 target price on shares of Humacyte in a research report on Thursday. Finally, Williams Trading set a $1.00 target price on shares of Humacyte in a research note on Friday, October 16th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $4.48.
Get Our Latest Analysis on Humacyte
Humacyte Price Performance
Shares of Humacyte stock opened at $0.54 on Friday. The stock has a 50 day moving average of $0.49 and a 200 day moving average of $0.78. The company has a current ratio of 3.34, a quick ratio of 5.74 and a debt-to-equity ratio of 3.65. Humacyte has a fifty-two week low of $0.34 and a fifty-two week high of $1.52.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently modified their holdings of the company. Beacon Pointe Advisors LLC purchased a new stake in shares of Humacyte in the 2nd quarter valued at $28,000. Bank of New York Mellon Corp acquired a new position in Humacyte during the 2nd quarter worth about $44,000. State Street Corp lifted its stake in Humacyte by 6.9% during the 3rd quarter. State Street Corp now owns 900,646 shares of the company’s stock worth $466,000 after acquiring an additional 58,109 shares in the last quarter. Sei Investments Co. purchased a new position in Humacyte during the 1st quarter valued at about $56,000. Finally, Miramontes Capital LLC purchased a new position in Humacyte during the 2nd quarter valued at about $85,000. 44.71% of the stock is currently owned by hedge funds and other institutional investors.
About Humacyte
Humacyte, Inc. is a biotechnology company developing bioengineered human tissues for vascular repair and other medical applications. Its technology uses human vascular cells to create vessels that are processed to remove the cells, leaving an acellular structure designed for implantation. The company’s lead product, Symvess, is an acellular tissue-engineered vessel for treating extremity arterial injuries in adults when a patient’s own vein cannot be used for surgical revascularization. The U.S. Food and Drug Administration approved Symvess in December 2024.
Further Reading
- Five stocks we like better than Humacyte
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Humacyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humacyte and related companies with MarketBeat.com's FREE daily email newsletter.
